Pharmaceutical
Technology
Health

Catabasis

$7.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-1.35%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Catabasis and other stocks, options, ETFs, and crypto commission-free!

About

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. Read More The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.

Employees
24
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
83.81M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
124.71K
High Today
$7.73
Low Today
$7.10
Open Price
$7.52
Volume
67.29K
52 Week High
$17.60
52 Week Low
$3.60

Collections

Pharmaceutical
Technology
Health
Biotechnology
Therapy
2015 IPO
US
North America

News

Yahoo FinanceMay 15

SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ...

- By insider Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, SV Life Sciences Advisers, LLC. As of 2019Q1, SV Life Sciences Advisers, LLC owns 7 stocks with a total value of $150 million. These are the details of the buys and sells. New Purchases: CATB, CATB, Reduced Positions: KALV, AVRO, DCPH, F...

123
Seeking AlphaMay 14

Catabasis Pharma net loss improves in Q1

Catabasis Pharmaceuticals (CATB) Q1 results: Revenues: $0; R&D Expense: $4.2M (-19.2%); SG&A: $2.1M (-12.5%); Net Loss: ($6M) (+22.1%); Loss Per Share: ($0.62) (+78.5%); Quick Assets: $51.7M (+37.5%); CF Ops (3M): ($6.6M) (+2.9%). Top-line results from the Phase 3 PolarisDMD trial expected in H2 2020, commercial registration of edasalonexent expected in early 2021. Shares are up 5% premarket. Previously: Catabasis Pharmaceuticals beats by $0.07 (May 14)...

49
Yahoo FinanceMay 2

Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy (DMD) from the MoveDMD trial open-label extension at the American Academy of Neurology 71st Annual Meeting to be held May 4 to May 10, 2019 in Philadelphia, PA. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System...

140

Earnings

-$0.90
-$0.63
-$0.35
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.69 per share
Actual
-$0.62 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.